Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects “robust” ...

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal ...

“S&P 500 annual return dispersion in 2024 rose to 70 percentage points, the highest level outside of recessions since 2007,” David Kostin, strategist at Goldman Sachs ... 20.5 Moderna Inc ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...